Royal London Asset Management’s Royalty Pharma RPRX Stock Holding History

Royal London Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242M	Buy	4,319,595 +511,242	+13%	+$26.6M	0.45%	39
2026 Q1	$183M	Buy	3,808,353 +3,628,670	+2,019%	+$159M	0.38%	48
2025 Q4	$6.94M	Buy	179,683 +1,212	+0.7%	+$46.2K	0.01%	500
2025 Q3	$6.3M	Hold	178,471	–	–	0.01%	517
2025 Q2	$6.43M	Sell	178,471 -3,073	-2%	-$102K	0.01%	520
2025 Q1	$5.65M	Buy	181,544 +3,849	+2%	+$122K	0.01%	550
2024 Q4	$4.53M	Buy	177,695 +17,511	+11%	+$464K	0.01%	561
2024 Q3	$4.53M	Buy	160,184 +4,307	+3%	+$119K	0.01%	563
2024 Q2	$4.11M	Sell	155,877 -183,688	-54%	-$5.09M	0.01%	568
2024 Q1	$10.3M	Buy	339,565 +17,769	+6%	+$524K	0.03%	395
2023 Q4	$9.04M	Buy	321,796 +3,282	+1%	+$90.2K	0.03%	401
2023 Q3	$8.65M	Buy	318,514 +52,524	+20%	+$1.56M	0.03%	399
2023 Q2	$8.17M	Buy	265,990 +123,566	+87%	+$4.19M	0.03%	401
2023 Q1	$5.13M	Buy	142,424 +14,803	+12%	+$549K	0.02%	468
2022 Q4	$5.04M	Buy	127,621 +7,612	+6%	+$318K	0.02%	451
2022 Q3	$4.82M	Sell	120,009 -3,979	-3%	-$170K	0.02%	438
2022 Q2	$5.22M	Hold	123,988	–	–	0.02%	437
2022 Q1	$4.83M	Buy	123,988 +5,904	+5%	+$232K	0.02%	511
2021 Q4	$4.71M	Hold	118,084	–	–	0.02%	508
2021 Q3	$4.27M	Hold	118,084	–	–	0.02%	535
2021 Q2	$4.84M	Hold	118,084	–	–	0.02%	523
2021 Q1	$5.15M	Buy	+118,084	New	+$5.6M	0.02%	486

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal London Asset Management's RPRX Position: Q2 2026 in Review

Royal London Asset Management increased its Royalty Pharma (RPRX) stake by 13% in Q2 2026, buying an estimated $26.6M and bringing the position to 4,319,595 shares worth $242M. The position accounts for 0.45% of the portfolio, ranked #39.

Royal London Asset Management first reported a position in RPRX in Q1 2021 and has held it in 22 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Royal London Asset Management held 4,319,595 shares of Royalty Pharma worth $242M as of Q2 2026.
Royal London Asset Management bought 511,242 Royalty Pharma shares in Q2 2026, an estimated $26.6M.
Royalty Pharma made up 0.45% of Royal London Asset Management's portfolio in Q2 2026, its #39 holding.
Royal London Asset Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 22 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.